Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24814425 | 0.92 | GAA (0.47) | POLBGAASMN1; SMN2PKMALDH1A1 | |
| SCHEMBL29986907 | 0.92 | GAA (0.47) | POLBGAASMN1; SMN2PKMALDH1A1 | |
| SCHEMBL24814454 | 0.90 | DPP9 (0.44) | GAAALDH1A1TSHR | |
| SCHEMBL29986069 | 0.81 | TAS1R3 (0.50) | POLBSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL29986247 | 0.81 | TAS1R3 (0.47) | POLBGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL24816196 | 0.81 | TAS1R3 (0.50) | POLBSMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL24814422 | 0.81 | TAS1R3 (0.47) | POLBGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL29986800 | 0.74 | TAS1R3 (0.46) | POLBGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL24814458 | 0.74 | TAS1R3 (0.46) | POLBGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL24814430 | 0.73 | SMN1; SMN2 (0.55) | POLBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-29 | — | — | US | disclosed |
| WO-2022251343-A2 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411418-A1 | CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF | CISD2, CISD1, FECH | POLB 4115/4885GAA 2875/4885SMN1; SMN2 1176/4885 |
| US-11827629-B2 | CDGSH iron sulfur domain 2 activators and use thereof | CISD2, CISD1, FECH | POLB 4115/4885GAA 2875/4885SMN1; SMN2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.